Answers are grounded in this paper and cite their sources.
Cutaneous squamous cell carcinoma (cSCC) is typically managed successfully with surgical excision, yet a subset of tumors exhibit aggressive behavior with regional and distant metastases. Until recently, systemic treatment options for advanced disease were limited. The introduction of immune checkpoint inhibitors has significantly expanded treatment options for unresectable and metastatic cSCC. We report the case of a man with rapidly progressive cSCC of the forehead with cervical lymph node involvement who demonstrated significant clinical and radiographic improvement following treatment with cemiplimab, a programmed cell death-1 (PD-1) inhibitor. Treatment was initiated for unresectable disease and resulted in marked tumor regression, allowing for subsequent surgical resection. Final pathology demonstrated no residual carcinoma, consistent with a complete pathologic response. This case highlights the potential role of PD-1 inhibition in downstaging advanced cSCC and enabling definitive surgical management.
No takes yet. Share an insight, caveat, or question.
Amid-Toby et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: